Prevention of Acute Sickle Cell Crisis: Review of the NEJM Report

Leonard Goldstein, Victoria A Troncoso, Roya Vahdatinia

Research output: Contribution to journalArticlepeer-review

Abstract

Commentary on the latest phase 2 results of crizanlizumab, a novel pharmaceutical agent for the prevention of vaso-occlusive crises in patients suffering from sickle cell disease.

Disciplines

  • Hematology

Cite this